Thomas Laughren

6.8k total citations · 1 hit paper
45 papers, 2.8k citations indexed

About

Thomas Laughren is a scholar working on Psychiatry and Mental health, Pharmacology and Economics and Econometrics. According to data from OpenAlex, Thomas Laughren has authored 45 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Psychiatry and Mental health, 15 papers in Pharmacology and 9 papers in Economics and Econometrics. Recurrent topics in Thomas Laughren's work include Treatment of Major Depression (15 papers), Schizophrenia research and treatment (12 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Thomas Laughren is often cited by papers focused on Treatment of Major Depression (15 papers), Schizophrenia research and treatment (12 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Thomas Laughren collaborates with scholars based in United States, Switzerland and United Kingdom. Thomas Laughren's co-authors include Tarek A. Hammad, Judith A. Racoosin, Walter A. Brown, Ni A. Khin, Yeh‐Fong Chen, Peiling Yang, Robert Temple, G. D. Rochester, Marc B. Stone and Mark Levenson and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and Journal of the American Academy of Child & Adolescent Psychiatry.

In The Last Decade

Thomas Laughren

43 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Suicidality in Pediatric Patients Treated With Antidepressant Drugs

2006 734 citations Tarek A. Hammad, Thomas Laughren et al. Archives of General Psychiatry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Laughren United States	24	1.3k	978	730	439	350	45	2.8k
Manit Srisurapanont Thailand	30	1.4k 1.1×	677 0.7×	708 1.0×	435 1.0×	449 1.3×	126	3.6k
Arif Khan United States	20	1.3k 1.0×	631 0.6×	827 1.1×	355 0.8×	440 1.3×	42	2.4k
David M. Gardner Canada	30	2.0k 1.5×	937 1.0×	431 0.6×	390 0.9×	535 1.5×	123	4.0k
Marcia G. Toprac United States	26	1.8k 1.4×	949 1.0×	995 1.4×	743 1.7×	251 0.7×	40	3.3k
Ihsan M. Salloum United States	36	1.8k 1.4×	1.3k 1.3×	467 0.6×	483 1.1×	270 0.8×	120	3.9k
Hugh McGuire United Kingdom	17	817 0.6×	1.0k 1.1×	1.0k 1.4×	633 1.4×	261 0.7×	25	3.2k
Hannu Koponen Finland	39	2.0k 1.6×	1.0k 1.1×	791 1.1×	877 2.0×	537 1.5×	201	4.9k
Stuart N. Seidman United States	28	1.4k 1.1×	661 0.7×	643 0.9×	270 0.6×	388 1.1×	46	3.3k
Jorge A. Cervilla Spain	29	1.1k 0.9×	973 1.0×	341 0.5×	317 0.7×	254 0.7×	109	2.7k
Jenny Guidi Italy	33	975 0.8×	1.1k 1.1×	625 0.9×	880 2.0×	251 0.7×	73	3.5k

Countries citing papers authored by Thomas Laughren

Since Specialization

Citations

This map shows the geographic impact of Thomas Laughren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Laughren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Laughren more than expected).

Fields of papers citing papers by Thomas Laughren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Laughren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Laughren. The network helps show where Thomas Laughren may publish in the future.

Co-authorship network of co-authors of Thomas Laughren

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Laughren. A scholar is included among the top collaborators of Thomas Laughren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Laughren. Thomas Laughren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thase, Michael E., Ewa Wajs, Joseph M. Trombello, et al.. (2025). 182. Seltorexant, Adjunctive to Antidepressants, in Adults With Major Depressive Disorder With Insomnia Symptoms: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Biological Psychiatry. 97(9). S169–S170.

Schooler, Nina R., Robert W. Buchanan, Thomas Laughren, et al.. (2015). Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms. Schizophrenia Research. 162(1-3). 169–174. 27 indexed citations

Chen, Yeh‐Fong, Thomas Laughren, Paul A. David, et al.. (2014). Review of Maintenance Trials for Major Depressive Disorder. The Journal of Clinical Psychiatry. 75(3). 205–214. 88 indexed citations

Calabrese, Joseph R., Maurizio Fava, George Garibaldi, et al.. (2014). Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders. Journal of Affective Disorders. 168. 439–451. 49 indexed citations

Freeman, Marlene P., et al.. (2013). Female Reproductive Life Cycle and Hormones: Methodology to Improve Clinical Trials. The Journal of Clinical Psychiatry. 74(10). 1018–1021. 3 indexed citations

Sun, Wan, Thomas Laughren, Hao‐Jie Zhu, Günther Hochhaus, & Yaning Wang. (2013). Development of a placebo effect model combined with a dropout model for bipolar disorder. Journal of Pharmacokinetics and Pharmacodynamics. 40(3). 359–368. 11 indexed citations

Younis, Islam R., Thomas Laughren, Yaning Wang, Mitchell Mathis, & Jogarao Gobburu. (2013). An Integrated Approach for Establishing Dosing Recommendations. Journal of Clinical Psychopharmacology. 33(2). 152–156. 4 indexed citations

Rogers, Hobart, Atul Bhattaram, Issam Zineh, et al.. (2012). CYP2D6 Genotype Information to Guide Pimozide Treatment in Adult and Pediatric Patients. The Journal of Clinical Psychiatry. 73(9). 1187–1190. 26 indexed citations

Khin, Ni A., Yeh‐Fong Chen, Yang Yang, Peiling Yang, & Thomas Laughren. (2012). Exploratory Analyses of Efficacy Data From Schizophrenia Trials in Support of New Drug Applications Submitted to the US Food and Drug Administration. The Journal of Clinical Psychiatry. 73(6). 856–864. 63 indexed citations

10.

Khin, Ni A., Yeh‐Fong Chen, Yang Yang, Peiling Yang, & Thomas Laughren. (2011). Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications. The Journal of Clinical Psychiatry. 72(4). 464–472. 168 indexed citations

11.

Yu, Binbing, Venkatesh Atul Bhattaram, Hao Wang, et al.. (2011). Essential Pharmacokinetic Information for Drug Dosage Decisions: A Concise Visual Presentation in the Drug Label. Clinical Pharmacology & Therapeutics. 90(3). 471–474. 25 indexed citations

12.

Laughren, Thomas. (2010). What’s Next After 50 Years of Psychiatric Drug Development. The Journal of Clinical Psychiatry. 71(9). 1196–1204. 10 indexed citations

13.

Buchanan, R. W., Richard S.E. Keefe, Daniel Umbricht, et al.. (2010). The FDA-NIMH-MATRICS Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?. Schizophrenia Bulletin. 37(6). 1209–1217. 115 indexed citations

14.

Stone, Marc B., Thomas Laughren, Mark Levenson, et al.. (2009). Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 339(aug11 2). b2880–b2880. 400 indexed citations

15.

Hammad, Tarek A., Thomas Laughren, & Judith A. Racoosin. (2006). Suicide Rates in Short-term Randomized Controlled Trials of Newer Antidepressants. Journal of Clinical Psychopharmacology. 26(2). 203–207. 94 indexed citations

16.

Bellack, A.S., M. F. Green, Judith Α. Cook, et al.. (2006). Assessment of Community Functioning in People With Schizophrenia and Other Severe Mental Illnesses: A White Paper Based on an NIMH-Sponsored Workshop. Schizophrenia Bulletin. 33(3). 805–822. 176 indexed citations

17.

Hammad, Tarek A., Thomas Laughren, & Judith A. Racoosin. (2006). Suicidality in Pediatric Patients Treated With Antidepressant Drugs. Archives of General Psychiatry. 63(3). 332–332. 734 indexed citations breakdown →

18.

Laughren, Thomas & Robert Levin. (2005). Food and Drug Administration Perspective on Negative Symptoms in Schizophrenia as a Target for a Drug Treatment Claim. Schizophrenia Bulletin. 32(2). 220–222. 60 indexed citations

19.

Laughren, Thomas. (2003). Comorbid mood disorders and medical illness: a Food and Drug Administration perspective. Biological Psychiatry. 54(3). 195–199. 10 indexed citations

20.

Greist, John H., et al.. (1974). Suicide Risk Prediction: A New Approach*. Suicide and Life-Threatening Behavior. 4(4). 212–223. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact